Literature DB >> 28283199

Drugs and Driving Research in Medicinal Drug Development.

J G Ramaekers1.   

Abstract

Medicinal drugs that cause drowsiness and inattentiveness may impair driving. The FDA recently emphasized that standardized procedures for measuring drug effects on driving are needed as part of drug registration. Here, I provide an overview of a standardized on-the-road driving test that offers maximal drug sensitivity and uses a real-life outcome measure of driver impairment that is strongly associated with crash risk.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28283199     DOI: 10.1016/j.tips.2017.01.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  12 in total

1.  Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.

Authors:  Thomas R Arkell; Frederick Vinckenbosch; Richard C Kevin; Eef L Theunissen; Iain S McGregor; Johannes G Ramaekers
Journal:  JAMA       Date:  2020-12-01       Impact factor: 56.272

2.  Comparing objective wakefulness and vigilance tests to on-the-road driving performance in narcolepsy and idiopathic hypersomnia.

Authors:  Denise Bijlenga; Bram Urbanus; Nick N J J M van der Sluiszen; Sebastiaan Overeem; Jan G Ramaekers; Annemiek Vermeeren; Gert Jan Lammers
Journal:  J Sleep Res       Date:  2021-11-09       Impact factor: 5.296

3.  Use of driving-impairing medicines by a Spanish population: a population-based registry study.

Authors:  Eduardo Gutierrez-Abejón; Francisco Herrera-Gómez; Paloma Criado-Espegel; F Javier Alvarez
Journal:  BMJ Open       Date:  2017-11-22       Impact factor: 2.692

4.  A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers.

Authors:  Maren Cecilie Strand; Vigdis Vindenes; Hallvard Gjerde; Jørg Gustav Mørland; Johannes G Ramaekers
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

5.  A Nationwide Population-Based Study on the Association between Land Transport Accident and Peripheral Vestibular Disorders.

Authors:  Herng-Ching Lin; Sudha Xirasagar; Chia-Hui Wang; Yen-Fu Cheng; Tsai-Ching Liu; Tzong-Hann Yang
Journal:  Int J Environ Res Public Health       Date:  2021-06-18       Impact factor: 3.390

6.  The Problem of Benzodiazepine Use and Its Extent in the Driver Population: A Population-Based Registry Study.

Authors:  Francisco Herrera-Gómez; Eduardo Gutierrez-Abejón; Paloma Criado-Espegel; F Javier Álvarez
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

7.  On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers.

Authors:  Annemiek Vermeeren; Stefan Jongen; Patricia Murphy; Margaret Moline; Gleb Filippov; Kate Pinner; Carlos Perdomo; Ishani Landry; Oneeb Majid; Anita C M Van Oers; Cees J Van Leeuwen; Johannes G Ramaekers; Eric F P M Vuurman
Journal:  Sleep       Date:  2019-04-01       Impact factor: 5.849

8.  Driving performance and neurocognitive skills of long-term users of benzodiazepine anxiolytics and hypnotics.

Authors:  Nick N J J M van der Sluiszen; Annemiek Vermeeren; Joris C Verster; Aurora J A E van de Loo; Joke H van Dijken; Janet L Veldstra; Karel A Brookhuis; Dick de Waard; Johannes G Ramaekers
Journal:  Hum Psychopharmacol       Date:  2019-11       Impact factor: 1.672

9.  Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment.

Authors:  F R J Vinckenbosch; A Vermeeren; J C Verster; J G Ramaekers; E F Vuurman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-03       Impact factor: 4.530

10.  Benzodiazepines in the oral fluid of Spanish drivers.

Authors:  Francisco Herrera-Gómez; Mercedes García-Mingo; F Javier Álvarez
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.